Patented design for all pen injector applications
Engineered to reduce the pain of regular injections for diabetes and other chronic conditions, Nanopass™ 34G Pen Needles feature a 22% thinner double-tapered needle and better flow than comparable 32G designs. Configured to fit most common pen injectors, Terumos’ asymmetric bevel aims to limit pain by significantly reducing penetration resistance1.
Designed for the subcutaneous injection of therapeutics including insulin and human growth hormones, Nanopass™ 34G Pen Needles offer the quality and supply reliability needed to meet drug developers’ toughest parenteral delivery challenges and product commercialization goals.
Patient's comfort in mind
- Asymmetric needle tip reduces skin trauma and pressure by cutting, not puncturing skin on penetration
- 34G needle 22% thinner than 32G, decreasing probability of touching pain receptors in the skin
- Optimized flow, less injection force than 32G needles (insulin)2
Engineered for automated environments
- Individually packed and sealed in an ergonomic plastic case for automated assembly and easier patient handling
Regulatory and Quality Aspects
- Radiation sterilization Sterility Assurance Level at least 10-6
- In compliance with applicable ISO standards and Pharmacopoeia
- CE-marked
- Proven track record of reliable supply assured by global operating company
